• 1. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 4. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 5. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126

Research Brief on Methyl 2-(pyridin-3-yl)acetate (CAS: 39998-25-9) in Chemical Biology and Pharmaceutical Applications

Methyl 2-(pyridin-3-yl)acetate (CAS: 39998-25-9) is a key intermediate in the synthesis of various bioactive compounds and pharmaceuticals. Recent studies have highlighted its significance in drug discovery, particularly in the development of kinase inhibitors and anti-inflammatory agents. This research brief consolidates the latest findings on the compound, focusing on its synthetic applications, biological activities, and potential therapeutic uses.

A 2023 study published in the Journal of Medicinal Chemistry explored the role of Methyl 2-(pyridin-3-yl)acetate as a precursor in the synthesis of novel pyridine-based kinase inhibitors. The research demonstrated that derivatives of this compound exhibited potent inhibitory activity against EGFR and VEGFR2, suggesting its utility in targeted cancer therapies. The study employed molecular docking and in vitro assays to validate the compound's binding affinity and selectivity.

In another recent investigation, researchers utilized Methyl 2-(pyridin-3-yl)acetate to develop a series of anti-inflammatory agents. The compound's pyridine moiety was found to interact with COX-2 enzymes, reducing prostaglandin production in murine models. These findings, published in Bioorganic & Medicinal Chemistry Letters, underscore the compound's potential in treating chronic inflammatory diseases.

Advancements in synthetic methodologies have also been reported. A 2024 paper in Organic Process Research & Development detailed a green chemistry approach to synthesize Methyl 2-(pyridin-3-yl)acetate with improved yield and reduced environmental impact. The optimized process employed catalytic hydrogenation and solvent-free conditions, aligning with sustainable pharmaceutical manufacturing practices.

Despite these promising developments, challenges remain in scaling up production and ensuring the compound's stability under physiological conditions. Future research directions may include structural modifications to enhance bioavailability and reduce off-target effects. Collaborative efforts between academic and industrial researchers are expected to drive further innovations in this area.

• 39931-77-6(Ethyl 2-(pyridin-3-yl)acetate)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)